174311-79-6

Basic information

• Product Name: 1H-Indole-7-carboxylicacid,6-amino-,ethylester(9CI)
• Synonyms: 1H-Indole-7-carboxylicacid,6-amino-,ethylester(9CI);Ethyl 6-amino-1H-indole-7-carboxylate;1H-Indole-7-carboxylic acid, 6-aMino-, ethyl ester
• CAS NO: 174311-79-6
• Molecular Formula: C11H12N2O2
• Molecular Weight: 204.23
• Product Categories: AMINOACID
• Mol File: 174311-79-6.mol

Chemical Properties

• Boiling Point: 400.122oC at 760 mmHg
• Flash Point: 195.787oC
• Appearance: /
• Density: 1.288g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.669
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 1H-Indole-7-carboxylicacid,6-amino-,ethylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole-7-carboxylicacid,6-amino-,ethylester(9CI)(174311-79-6)
• EPA Substance Registry System: 1H-Indole-7-carboxylicacid,6-amino-,ethylester(9CI)(174311-79-6)

Safety Data

• Hazardous Substances Data: 174311-79-6(Hazardous Substances Data)

Usage

Uses

Due to the limited information available on the uses and characteristics of 1H-Indole-7-carboxylic acid, 6-amino-, ethyl ester (9CI), it is difficult to provide specific applications for 1H-Indole-7-carboxylicacid,6-amino-,ethylester(9CI). However, based on its chemical structure and the properties of similar indole compounds, some potential uses can be inferred:
Used in Pharmaceutical Industry:
1H-Indole-7-carboxylic acid, 6-amino-, ethyl ester (9CI) could be used as an intermediate in the synthesis of pharmaceutical compounds, particularly those targeting the central nervous system or exhibiting neuroprotective properties. The presence of the 6-amino group and the ethyl ester functional group may allow for further chemical modifications to enhance the compound's bioactivity and pharmacokinetic properties.
Used in Chemical Research:
1H-Indole-7-carboxylicacid,6-amino-,ethylester(9CI) may also be utilized in chemical research for studying the structure-activity relationships of indole-based compounds and their potential applications in various fields, such as agrochemicals, materials science, or environmental chemistry.

InChI:InChI=1/C11H12N2O2/c1-2-15-11(14)9-8(12)4-3-7-5-6-13-10(7)9/h3-6,13H,2,12H2,1H3

Upstream product

• 174311-78-5 (E)-3-<2-(dimethylamino)ethenyl>-2,6-dinitrobenzoic acid ethyl ester 
• 3478-09-9 3-methyl-2,6-dinitrobenzoic acid 
• 90001-60-8 2,6-Dinitro-3-methyl-benzoylchlorid 
• 873055-34-6 3-(2-dimethylamino-vinyl)-2,6-dinitro-benzoic acid ethyl ester 
• 99-04-7 m-Toluic acid 
• 103041-13-0 3-methyl-2,6-dinitrobenzoic acid ethyl ester 
• 54064-40-3 5-methyl-2-nitrobenzoic acid ethyl ester 
• 3113-72-2 5-methyl-2-nitrobenzoic acid 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.